Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trogopterus dung, known as **Wu Ling Zhi** in Traditional Chinese Medicine (TCM), is the dried feces of the complex-toothed flying squirrel (*Trogopterus xanthipes*). It is traditionally classified as a blood-regulating agent used to promote blood circulation, dissipate blood stasis, and alleviate pain. Modern pharmacological research indicates that it contains various bile acids and organic compounds that contribute to its anti-inflammatory, anti-tumor, and cardioprotective effects. It is a key component in several Chinese patent medicines, such as **Pingxiao Capsule**, which is used as an adjuvant therapy for breast cancer, and **Gu Ben Pei Yuan San**, which has been studied for its potential to improve myocardial repair after injury. Its mechanisms of action include the inhibition of **Toll-like receptor 4 (TLR4)** expression and the reduction of **Cyclin D1** levels, which may mediate its therapeutic benefits in immune thrombocytopenia and malignant neoplasms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trogopterus dung.